Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 19/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 18/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 10/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.40 |
| ▸ | TSHR | P16473 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 6/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1196784 | 0.82 | CYP1A2 (0.40) | CYP1A2CYP3A4CLK4HSD17B10CYP2D6 | |
| SCHEMBL5833062 | 0.79 | CYP1A2 (0.38) | CYP1A2CYP3A4CLK4HSD17B10CYP2D6 | |
| SCHEMBL5833413 | 0.79 | CYP1A2 (0.38) | CYP1A2CYP3A4CLK4HSD17B10CYP2D6 | |
| SCHEMBL24180048 | 0.79 | CYP1A2 (0.42) | CYP1A2CYP3A4CLK4HSD17B10CYP2D6 | |
| SCHEMBL14279028 | 0.79 | OPRM1 (0.39) | CYP1A2CYP3A4CLK4HSD17B10CYP2D6 | |
| SCHEMBL3984933 | 0.78 | CYP1A2 (0.42) | CYP1A2CYP3A4CLK4HSD17B10CYP2D6 | |
| Ethylenediamine SCHEMBL5884629 | 0.77 | TLR7 (0.39) | CYP1A2CYP3A4CLK4HSD17B10CYP2D6 | |
| SCHEMBL15587859 | 0.77 | CYP1A2 (0.41) | CYP1A2CYP3A4CLK4HSD17B10CYP2D6 | |
| SCHEMBL402004 | 0.76 | CYP1A2 (0.41) | CYP1A2CYP3A4CLK4HSD17B10CYP2D6 | |
| SCHEMBL5884618 | 0.76 | TLR7 (0.36) | CYP1A2CYP3A4CLK4HSD17B10CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4268824-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZINE DERIVATIVES USEFUL AS A MEDICAMENT | Manros Therapeutics (FR) | 2023-11-01 | — | — | EP | disclosed |
| US-8372973-B2 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-12 | — | — | US | disclosed |
| CN-101460453-B | Novel sulfonamide compounds | ACTELION PHARMACEUTICALS LTD | 2012-10-03 | — | — | CN | disclosed |
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | COATS STEVEN J (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | JANSSEN PHARMACEUTICA, NV (BE) | 2011-12-29 | — | — | US | disclosed |
| US-8003654-B2 | N-glycinsulfonamide derivatives and uses as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-23 | — | — | US | disclosed |
| US-7902358-B2 | Gastrointestinal disorders; inflammatory bowel disorders; gastroesophageal reflux, constipation; diarrhea | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-08 | — | — | US | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-7799915-B2 | Anilino-pyrimidine analogs | WYETH LLC (US) | 2010-09-21 | — | — | US | disclosed |
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-11-05 | — | — | US | disclosed |
| CN-101460453-A | Novel sulfonamide compounds | ACTELION PHARMACEUTICALS LTD (CH) | 2009-06-17 | — | — | CN | disclosed |
| EP-2007717-A1 | NOVEL SULFONAMIDE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-31 | — | — | EP | disclosed |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-11-20 | — | — | US | disclosed |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-10-30 | — | — | US | disclosed |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | WYETH (US) | 2008-10-23 | — | — | US | disclosed |
| US-7320986-B2 | Fused tri and tetra-cyclic pyrazole kinase inhibitors | ABBOTT LABORTORIES (US) | 2008-01-22 | — | — | US | disclosed |
| WO-2007116374-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | WYETH (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028997-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS | PROKR1, PROKR2, GIPR | CYP1A2 3611/4885CYP3A4 3830/4885CLK4 4389/4885 |
| US-20110319400-A1 | PROKINETICIN 1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | PROKR1, OPRL1, PROKR2 | CYP1A2 3333/4885CYP3A4 4099/4885CLK4 3686/4885 |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, RUNX1, ACIN1 | CYP1A2 2808/4885CYP3A4 3114/4885CLK4 4036/4885 |
| US-20080269225-A1 | Prokineticin 1 receptor antagonists | PROKR1, PROKR2, GIPR | CYP1A2 3611/4885CYP3A4 3830/4885CLK4 4389/4885 |
| US-20070244140-A1 | Anilino-pyrimidine phenyl and benzothiophene analogs | HPRT1, APRT, NUDT1 | CYP1A2 255/4885CYP3A4 195/4885CLK4 3921/4885 |
| US-20080262010-A1 | CRYSTALLINE POLYMORPHS OF N-(3-(DIMETHYLAMINO)PROPYL)-4-(4-(3-FLUORO-4-METHOXYPHENYL) PYRIMIDIN-2-YLAMINO) BENZENESULFONAMIDE AS D-GLUCORONATE SALTS | GALE, UGGT1, UGT1A3 | CYP1A2 385/4885CYP3A4 57/4885CLK4 2963/4885 |
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | HCRTR2, HCRTR1, NPSR1 | CYP1A2 3485/4885CYP3A4 3312/4885CLK4 4331/4885 |
| US-20080287445-A1 | Prokineticin 2 receptor antagonists | PROKR2, PROKR1, GIPR | CYP1A2 2416/4885CYP3A4 3970/4885CLK4 3800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.